Semaglutide protects diabetic kidneys by activating β-Klotho to inhibit ferroptosis via cAMP-PKA-CREB signaling
Semaglutide alleviates diabetic kidney disease by upregulating β-Klotho through cAMP-PKA-CREB signaling, which activates AMPK to inhibit ferroptosis (iron-dependent cell death), reducing renal inflammation and fibrosis.
Quick Facts
What This Study Found
Semaglutide → cAMP-PKA-CREB → ↑KLB (β-Klotho) → AMPK activation → ↓ferroptosis (↓iron, ↓fatty acid synthesis, ↑antioxidant). Result: ↓renal inflammation, ↓fibrosis. Validated in patients, animals, HK-2 cells. KLB identified by transcriptome sequencing.
Key Numbers
How They Did This
Transcriptome sequencing for target identification. DKD patient samples, animal models, HK-2 kidney cells. cAMP-PKA-CREB pathway analysis. AMPK signaling. Ferroptosis markers (iron, lipid peroxidation, antioxidant).
Why This Research Matters
DKD is the leading cause of end-stage kidney failure. Identifying the exact molecular pathway (cAMP→KLB→AMPK→anti-ferroptosis) by which semaglutide protects kidneys enables targeted therapeutic optimization.
The Bigger Picture
Ferroptosis is increasingly recognized as a driver of organ damage in diabetes. Semaglutide's ability to suppress it through KLB provides a precise molecular target for renal protection and potentially for other organs affected by ferroptosis.
What This Study Doesn't Tell Us
Complex pathway—causation at each step needs further validation. KLB upregulation mechanism via cAMP is novel and needs independent confirmation. HK-2 cells may not fully represent in vivo kidney tubules.
Questions This Raises
- ?Could KLB-targeted drugs replicate semaglutide's renal protection?
- ?Is ferroptosis inhibition the key to preventing all diabetic organ damage?
- ?Would ferroptosis markers serve as clinical biomarkers for DKD treatment response?
Trust & Context
- Key Stat:
- Ferroptosis inhibition = kidney protection Semaglutide activates β-Klotho via cAMP signaling to suppress iron-dependent cell death in diabetic kidneys—a precise, targetable molecular mechanism
- Evidence Grade:
- Multi-level study (transcriptomics, patients, animals, cells). Strong mechanistic evidence with clinical validation.
- Study Age:
- Published in 2025.
- Original Title:
- GLP-1 Receptor Agonists Alleviate Diabetic Kidney Injury via β-Klotho-Mediated Ferroptosis Inhibition.
- Published In:
- Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(4), e2409781 (2025)
- Authors:
- Tian, Shasha, Zhou, Saijun, Wu, Weixi, Lin, Yao, Wang, Tongdan, Sun, Haizhen, A-Ni-Wan, A-Shan-Jiang, Li, Yaru, Wang, Chongyang, Li, Xiaogang, Yu, Pei, Zhao, Yanjun
- Database ID:
- RPEP-13807
Evidence Hierarchy
Frequently Asked Questions
How does semaglutide protect the kidneys?
This study identified the complete molecular chain: semaglutide activates cAMP signaling → which increases β-Klotho protein → which activates AMPK → which stops ferroptosis (a type of iron-dependent cell death that damages kidneys). By stopping ferroptosis, kidney inflammation and scarring are reduced.
What is ferroptosis?
Ferroptosis is a recently discovered form of cell death driven by iron accumulation and lipid damage. It is increasingly recognized as a key driver of kidney damage in diabetes. By blocking ferroptosis through β-Klotho activation, semaglutide protects kidney cells from this destructive process.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13807APA
Tian, Shasha; Zhou, Saijun; Wu, Weixi; Lin, Yao; Wang, Tongdan; Sun, Haizhen; A-Ni-Wan, A-Shan-Jiang; Li, Yaru; Wang, Chongyang; Li, Xiaogang; Yu, Pei; Zhao, Yanjun. (2025). GLP-1 Receptor Agonists Alleviate Diabetic Kidney Injury via β-Klotho-Mediated Ferroptosis Inhibition.. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(4), e2409781. https://doi.org/10.1002/advs.202409781
MLA
Tian, Shasha, et al. "GLP-1 Receptor Agonists Alleviate Diabetic Kidney Injury via β-Klotho-Mediated Ferroptosis Inhibition.." Advanced science (Weinheim, 2025. https://doi.org/10.1002/advs.202409781
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 Receptor Agonists Alleviate Diabetic Kidney Injury via..." RPEP-13807. Retrieved from https://rethinkpeptides.com/research/tian-2025-glp1-receptor-agonists-alleviate
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.